ScripStrides Pharma Science Limited is shifting focus to chronic therapies from acute as it seeks to weed out excessive seasonality in its US business and move towards a US revenue target of $400-500m tha
Generics BulletinStrides Pharma Science has struck a deal with fellow Indian firm Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture and sell four nasal sprays for global markets. Citing